Tag Archives | Alpharadin

Are you adapting to the changing prostate cancer market?

The prostate cancer market continues to evolve at a fast pace.  Companies with products on the market or in development will need to adapt their marketing strategy to the changing prostate cancer market dynamics.  Some of the recent news includes: MDV3100 shows 4.8 improvement in median overall survival Sally Church, PhD on Pharma Strategy Blog […]

Continue Reading

MDV3100 in Advanced Prostate Cancer

The fast moving prostate cancer market took another leap forward last week with the announcement of positive phase III data for Medivation’s MDV3100. As reported by Sally Church on Pharma Strategy Blog, Medivation announced that the interim analysis of the AFFIRM trial showed a 4.8 month increase in overall survival (OS) compared to placebo. Although […]

Continue Reading

Top posts on Biotech Strategy Blog

Last week, Biotech Strategy Blog celebrated one year of publication! Two of the most read posts on Biotech Strategy Blog in its first year were: Lucentis v Avastin CATT trial results in AMD (briefing at ARVO) Prostate Cancer Intervention versus Observation (PIVOT) trial data (presented in plenary session at AUA) You can read more on […]

Continue Reading

Alpharadin may change standard of care for prostate cancer patients with bone mets

We recently attended the 2011 European Multidisciplinary Cancer Congress in Stockholm. Paradigm shifting data in breast cancer and advanced prostate cancer were presented at what turned out to be an excellent meeting in a charming, if expensive, city. Sally Church (@MaverickNY) live tweeted several sessions from the meeting and was name the “Top Twitter Influencer” […]

Continue Reading

2011 ESMO ESTRO ECCO Cancer Congress Prostate Cancer News

It’s exciting to see new products that make a difference to patients come to market. Multiple treatments improve overall survival (OS) in prostate cancer patients: docetaxel, cabazitaxel, sipuleucel-T, abiraterone acetate and now, radium-223 choloride. The phase 3 trial results for radium 223 chloride were presented at the 2011 European Multidisciplinary Cancer Congress (ESMO, ECCO, ESTRO) […]

Continue Reading

Follow coverage of 2011 Stockholm Cancer Congress #EMCC2011

The 2011 Stockholm Multidisciplinary Cancer Congress (more commonly known as ECCO 2011 or ESMO 2011) is underway in Stockholm, Sweden. Pieter Droppert (@3NT) will be writing on Biotech Strategy Blog from the meeting and in particular the new data on prostate cancer that will be presented, in particular the phase 3 Alpharadin ALSYMPCA trial data […]

Continue Reading

Vismodegib best abstract at ECCO 2011 Stockholm Cancer Congress

Next week sees the start of the 2011 Stockholm Cancer Congress – a joint multidisciplinary meeting of ECCO, ESMO and ESTRO. What’s likely to be hot news from Stockholm? On Biotech Strategy Blog, Pieter Droppert has highlighted the phase III data to be presented at ECCO 2011 on Alpharadin (radium-223 chloride) in castration-resistant prostate cancer […]

Continue Reading

AUA 2011 Annual Meeting Prostate Cancer Highlights

The 2011 annual meeting of the American Urological Association (AUA) ended in Washington DC today. Some of the highlights of the meeting were written about on Pharma Strategy Blog and Biotech Strategy Blog, these include: PIVOT (Prostate Cancer Intervention versus Observation Study) The data from this study was presented in Tuesday’s plenary session by Dr […]

Continue Reading